Liver cirrosis and complication risk management

Cover Page

Cite item

Full Text

Abstract

Liver cirrhosis (LC) takes the main place in the structure of the pathology of the digestive system in terms of the frequency of mortality, as well as in the development of fatal and poorly controlled complications, which requires the search for effective methods for preventing the progression of the disease and the development of complications. The article provides updated information on the role of the intestinal microbiota, as well as endotoxemia and increased intestinal permeability syndromes in the pathophysiology of LC and its complications. The results of recent meta-analyses of the impact of dysbiotic disorders on the prognosis of the LC and the options for their correction are presented. Understanding of the significance of involvement of gut microbiota in the pathogenesis of LC has become one of the “levers of management” of the risks of complications of LC. In this case, the “liver–gut” axis can be considered to be the leading link to the formation of most of the main complications of LC.

About the authors

Igor G. Bakulin

Mechnikov North-Western State Medical University

Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0002-6151-2021

доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии

Russian Federation, Saint Petersburg

Inna A. Oganezova

Mechnikov North-Western State Medical University

Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0003-0844-4469

доктор медицинских наук, профессор, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии

Russian Federation, Saint Petersburg

Maria I. Skalinskaya

Mechnikov North-Western State Medical University

Author for correspondence.
Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0003-0769-8176

кандидат медицинских наук, доцент, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии

Russian Federation, Saint Petersburg

Ekaterina V. Skazyvaeva

Mechnikov North-Western State Medical University

Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0002-8563-6870

кандидат медицинских наук, доцент, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии

Russian Federation, Saint Petersburg

References

  1. Rowe IA. Lessons from Epidemiology: The Burden of Liver Disease. Dig Dis. 2017;35(4):304-9. doi: 10.1159/000456580
  2. Mokdad AA, Lopez АD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine. 2014;12:145. doi: 10.1186/s12916-014-0145-y
  3. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718-35. doi: 10.1016/j.jhep.2018.05.011
  4. Global status report on alcohol and health 2018. WHO, 2018. Available at: https://www.who.int/substance_abuse/publications/global_alcohol_report/en/ Accessed: 21.02.2021.
  5. Драпкина О.М., Самородская И.В., Болотова Е.В., Старинская М.А. Нозологическая структура потерянных лет потенциальной жизни в экономически активном возрасте в Российской Федерации в 2016 г. Профилактическая медицина. 2019;22(1):22-8 [Drapkina OМ, Samorodskaya IV, Bolotova EV, Starinskaya MA. The nosological structure of years of potential life lost in the economically active age in the Russian Federation in 2016. The Russian Journal of Preventive Medicine. 2019;22(1):22-8 (in Russian)]. doi: 10.17116/profmed20192201122
  6. Драпкина О.М., Корнеева О.Н., Ивашкин В.Т. Терапия неалкогольного стеатогепатита при метаболическом синдроме: фокус на эссенциальные фосфолипиды. Лечащий врач. 2010;2. Режим доступа: https://www.lvrach.ru/2010/02/12157759. Ссылка активна на 29.03.2021 [Drapkina OM, Korneeva ON, Ivashkin VT. Therapy non-alcoholic steatohepatitis with metabolic syndrome: focus on essential phospholipids. Lechashchij vrach. 2010;2. Available at: https://www.lvrach.ru/2010/02/12157759. Accessed: 29.03.2021 (in Russian)].
  7. Драпкина О.М. Неалкогольная жировая болезнь печени и метаболический синдром. Справочник поликлинического врача. 2008;3:71-4 [Drapkina OM. Non-alcoholic fatty liver disease and metabolic syndrome. Handbook for Practitioners Doctors. 2008;3:71-4 (in Russian)].
  8. Долгушина А.И., Олевская Е.Р., Тарасов А.Н., и др. Эпидемиология цирроза печени в Челябинской области по данным за 2006–2015 гг. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):72-8 [Dolgushina AI, Olevskaya YeR, Tarasov AN, et al. Liver cirrhosis epidemiology in Chelyabinsk region in 2006–2015. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):72-8 (in Russian)]. doi: 10.22416/1382-4376-2017-27-1-72-78
  9. Горный Б.Э., Калинина А.М. Связь интегральной оценки региональной алкогольной ситуации и смертности населения от некоторых хронических неинфекционных заболеваний. Профилактическая медицина. 2019;22(4):65-8 [Gorny BE, Kalinina AM. Relationship between the integral estimation of the regional alcohol situation and mortality from some chronic non-communicable diseases. The Russian Journal of Preventive Medicine. 2019;22(4):65-8 (in Russian)]. doi: 10.17116/profmed20192204165
  10. Бакулин И.Г., Варламичева А.А. Асцит, спонтанный бактериальный перитонит, гепаторенальный синдром: что общего в диагностике и лечении? Терапевтический архив. 2015;87(4):77-83 [Bakulin IG, Varlamicheva AA. Ascites, spontaneous bacterial peritonitis, hepatorenal syndrome: What is common in their diagnosis and treatment? Terapevticheskii Arkhiv (Ter. Arkh). 2015;87(4):77-83 (in Russian)]. doi: 10.17116/terarkh201587477-83
  11. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60. doi: 10.1016/j.jhep.2018.03.024
  12. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310-35. doi: 10.1002/hep.28906
  13. Бакулин И.Г. Клинико-патогенетическое обоснование коррекции недостаточности питания у раненых и больных с различными заболеваниями внутренних органов. М., 2004 [Bakulin IG. Clinical and pathogenetic justification of the correction of malnutrition in the wounded and patients with various diseases of the internal organs. Moscow, 2014 (in Russian)].
  14. Saleem S, Katragadda R, Weissman S, Bleibel W. Morbidity and mortality of infections in the cirrhotic patients: a US population-based study. Gastroenterol Hepatol Bed Bench. 2019;12(3):233‐8. doi: 10.22037/ghfbb.v12i3.1657
  15. Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019;70:398-411. doi: 10.1016/j.jhep.2018.10.027
  16. Piano S, Singh V, Caraceni P, et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology. 2019;156(5):1368-80.e10. doi: 10.1053/j.gastro.2018.12.005
  17. Schultalbers M, Tergast TL, Simon N, et al. Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites. United European Gastroenterol J. 2020;8(5):567-76. doi: 10.1177/2050640620913732
  18. Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol. 2015;7(3):425‐42. doi: 10.4254/wjh.v7.i3.425
  19. Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol. 2019;25(39):5897-917. doi: 10.3748/wjg.v25.i39.5897
  20. Nicoletti A, Ponziani FR, Biolato M, et al. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019;25(33):4814-34. doi: 10.3748/wjg.v25.i33.4814
  21. Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12(Suppl. 1):24‐33. doi: 10.1007/s12072-017-9798-x
  22. Sakamaki A, Yokoyama K, Yamazaki F, et al. Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis. Intern Med. 2020;59(15):1849-53. doi: 10.2169/internalmedicine.4593-20
  23. Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol. 2019;10:293. doi: 10.3389/fimmu.2019.00293
  24. Dubinkina VB, Tyakht AV, Odintsova VY, et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017;5. doi: 10.1186/s40168-017-0359-2
  25. Масленников Р.В., Татаркина М.А., Маевская М.В., и др. Влияние синдрома избыточного бактериального роста и системного воспаления на абдоминальную гемодинамику у больных циррозом печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):52-61 [Maslennikov RV, Tatarkina MA, Mayevskaya MV, et al. The impact of bacterial overgrowth syndrome and systemic inflammation on abdominal hemodynamics in liver cirrhosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):52-61 (in Russian)]. doi: 10.22416/1382-4376-2017-27-4-52-61
  26. Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci. 2020;22(1):199. doi: 10.3390/ijms22010199
  27. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740‐8. doi: 10.1136/gutjnl-2015-310376
  28. Takagi T, Naito Y, Inoue R, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62(1):100‐5. doi: 10.3164/jcbn.17-78
  29. Tantai XX, Yang LB, Wei ZC, et al. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol. 2019;25(21):2683‐98. doi: 10.3748/wjg.v25.i21.2683
  30. Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64(4):1265-72. doi: 10.1002/hep.28737
  31. Wang J, Wu Y, Bi Q, et al. Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis. Hepatol Int. 2020. doi: 10.1007/s12072-019-10010-3
  32. Tsai CF, Chen MH, Wang YP, et al. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152(1):134-41. doi: 10.1053/j.gastro.2016.09.007
  33. Lin L, Hou L, Deng Y, et al. Acid suppression therapy and its association with spontaneous bacterial peritonitis incidence: A systemic review and meta-analysis. Hepatol Res. 2020;50(2):233-45. doi: 10.1111/hepr.13447
  34. Trikudanathan G, Israel J, Cappa J, O’Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta-analysis. Int J Clin Pract. 2011;65(6):674-8. doi: 10.1111/j.1742-1241.2011.02650.x
  35. De Roza MA, Kai L, Kam JW, et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol. 2019;25(33):4933‐44. doi: 10.3748/wjg.v25.i33.4933
  36. Kockerling D, Nathwani R, Forlano R, et al. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol. 2019;25(8):888‐908. doi: 10.3748/wjg.v25.i8.888
  37. Ghosh G, Jesudian AB. Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis. J Clin Exp Hepatol. 2019;9(2):257‐67. doi: 10.1016/j.jceh.2018.08.006
  38. Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol. 2018;11:1756284818800307. doi: 10.1177/1756284818800307
  39. Salehi S, Tranah TH, Lim S, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther. 2019;50(4):435‐41. doi: 10.1111/apt.15326
  40. Kang SH, Lee YB, Lee JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther. 2017;46(9):845‐55. doi: 10.1111/apt.14275
  41. Lv XY, Ding HG, Zheng JF, et al. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol. 2020;26(2):199-218. doi: 10.3748/wjg.v26.i2.199
  42. Soni H, Kumar‐MP, Sharma V, et al. Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta‐analysis. Hepatol Int. 2020;14(3):399-413. doi: 10.1007/s12072-020-10025-1
  43. Kaji K, Takaya H, Saikawa S, et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol. 2017;23(47):8355‐66. doi: 10.3748/wjg.v23.i47.8355.

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies